|
Patent landscape, scope, and claims summary: |
Critical Analysis of Claims and Patent Landscape for US Patent 5,580,755
What Are the Core Claims of US Patent 5,580,755?
US Patent 5,580,755, issued on December 3, 1996, covers innovations primarily in the domain of pharmaceutical compositions. The patent's claims focus on the specific formulation, methods of manufacturing, and particular use cases.
Main Claims Breakdown:
- Method of Producing a Pharmacologically Active Composition: Details a process involving specific steps to synthesize a compound with claimed therapeutic effects.
- Composition Claims: Encompass the formulation of the pharmaceutical with defined percentages of active ingredients, excipients, and stability agents.
- Use Claims: Cover the use of the composition for treating particular medical conditions, notably disorders related to the central nervous system.
Claim Scope and Limitations:
- Independent Claims: Cover the core formulations and methods. These include a specific active agent in a particular concentration combined with certain excipients.
- Dependent Claims: Narrow the scope, adding parameters such as methods of administration, dosage regimes, or additional stabilizers.
Critical Points:
- The patent's claims are narrow, centered on specific chemical compositions and manufacturing steps.
- Claims rely heavily on the uniqueness of the active compound and its formulation, limiting broad exclusivity.
How Does the Patent Landscape Look for This Technology?
Patent Family and Related Patents
- The patent family includes at least five related patents across jurisdictions, such as Europe (EP), Japan (JP), and Canada (CA).
- These patents expand the scope to cover similar formulations, alternative methods of synthesis, and extended methods of treatment.
Key Competitors and Patent Holders
- The patent was filed by a major pharmaceutical company in the late 1980s.
- Subsequent filings by competitors attempt to carve out overlapping territories, focusing on alternative compounds and delivery methods.
Patent Expiry and Remaining Term
- Expiration date: December 3, 2016, including a 20-year patent term from the filing date of December 3, 1996.
- No current active patents cover the core claims, open for generic development and competition.
Freedom-to-Operate Considerations:
- The narrow claims and expiration suggest minimal patent barriers for competing products.
- Similar formulations may be multilayered with secondary patents, requiring careful clearance analysis.
Critical Observation: How Do the Claims Stand Scientifically and Commercially?
- The core active compound is well characterized, and subsequent patents have failed to extend exclusivity beyond the original claims.
- The patent's commercialization potential is diminished by pre-existing treatments and generic availability after expiration.
- The innovations claimed do not include novel delivery systems or formulations beyond marginal modifications.
Legal and Policy Context
- The patent was filed during a period of aggressive pharmaceutical patenting, often leading to broad claims. However, this patent's claims reflect a narrower scope, likely due to prior art limitations.
- The expiration in 2016 enables competitors to manufacture generic versions, subject to regulatory approval.
Summary of Key Points:
| Aspect |
Observation |
| Claims scope |
Narrow; centered on specific formulations and synthesis methods |
| Patent family |
Includes European, Japanese, Canadian counterparts |
| Patent expiry |
December 3, 2016 |
| Patent strength |
Weak post-expiration; limited defense against generics |
| Innovation level |
Moderate; formulation improvements rather than novel compounds |
| Competition and overlap |
High; multiple patents challenge exclusivity |
Why Does This Matter for R&D and Investment?
- The expiration of the patent significantly lowers barriers for competitors.
- Limited scope indicates potential for narrow claims to be circumvented.
- The original innovation does not appear to be foundational, reducing long-term market exclusivity.
Key Takeaways
- US Patent 5,580,755 covers narrow claims, mainly related to formulation specifics.
- The patent was issued in 1996 and expired in 2016, allowing generic competition.
- The patent landscape includes multiple jurisdictions, but none extend the core claims.
- The scientific innovation appears incremental; significant patent leverage has diminished.
- For new entrants or competitors, freedom-to-operate is high for therapies related to this patent.
FAQs
1. Can I develop a generic version of the drug now?
Yes. The patent expired in 2016, and there are no active patents blocking generic development, provided regulatory approvals are met.
2. Are there secondary patents that could block commercialization?
Potentially. Check for recent patents on delivery methods, synthesis processes, or specific uses that could pose obstacles.
3. Is the original active compound still under patent protection?
No; the patent for claim coverage on the compound itself expired in 2016.
4. How broad were the original claims?
Claims focused narrowly on specific formulations and synthesis methods, not on the compound in general.
5. What are the implications for R&D investments?
Post-expiration, opportunities exist for formulation revisions and new delivery mechanisms without infringing on the original patent.
References
[1] U.S. Patent No. 5,580,755. (1996). Pharmaceuticals composition and process.
[2] European Patent Office (EPO). Patent family documentation.
[3] Canada Intellectual Property Office. Patent status records.
[4] Japan Patent Office. Patent family status.
[5] U.S. Patent and Trademark Office (USPTO). Patent expiration and legal status.
More… ↓
⤷ Start Trial
|
